Table 2.
General characteristics of the study population (initial cancer diagnosed 2000–2012) by preventive health service, Kaiser Permanente Southern California.
| Dyslipidemia screening1 |
Hypertension screening2 |
Influenza Vaccination3 |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer survivors | Non-cancer group | Total | Cancer survivors | Non-cancer group | Total | Cancer survivors | Non-cancer group | Total | |
| (n = 1900) | (n = 8102) | (n = 10002) | (n = 4894) | (n = 19450) | (n = 24344) | (n = 6779) | (n = 25,640) | (n = 32419) | |
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | |
| Follow-up period (years) | 4.00 (3.22) | 4.00 (3.29) | 4.00 (3.27) | 4.30 (2.61) | 4.4 (2.63) | 4.4 (2.63) | 5.2 (3.88) | 5.2 (3.88) | 5.2 (3.88) |
| Age7 | 35.20 (3.47) | 35.20 (3.48) | 35.2 (3.48) | 31.1 (6.54) | 31.3 (6.44) | 31.2 (6.46) | 31.3 (6.53) | 31.3 (6.54) | 31.3 (6.54) |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Age group7 | |||||||||
| 15–19 years | −8 (0.05%) | −8 (0.02%) | −8 (0.03%) | 387 (7.91%) | 1402 (7.21%) | 1789 (7.35%) | 521 (7.69%) | 1994 (7.78%) | 2515 (7.76%) |
| 20–29 years | 137 (7.21%) | 568 (7.01%) | 705 (7.05%) | 1294 (26.44%) | 5027 (25.85%) | 6321 (25.97%) | 1707 (25.18%) | 6451 (25.16%) | 8158 (25.16%) |
| 30–39 years | 1762 (92.74%) | 7532 (92.96%) | 9294 (92.92%) | 3213 (65.65%) | 13021 (66.95%) | 16234 (66.69%) | 4551 (67.13%) | 17195 (67.06%) | 21746 (67.08%) |
| Sex | |||||||||
| Female | 762 (40.11%) | 3311 (40.87%) | 4073 (40.72%) | 3227 (65.94%) | 12852 (66.08%) | 16079 (66.05%) | 4427 (65.30%) | 16729 (65.25%) | 21156 (65.26%) |
| Male | 1138 (59.89%) | 4791 (59.13%) | 5929 (59.28%) | 1667 (34.06%) | 6598 (33.92%) | 8265 (33.95%) | 2352 (34.70%) | 8911 (34.75%) | 11263 (34.74%) |
| Race/ethnicity | |||||||||
| Asian/Pacific Islander | 178 (9.37%) | 829 (10.23%) | 1007 (10.07%) | 516 (10.54%) | 2125 (10.93%) | 2641 (10.85%) | 696 (10.27%) | 2575 (10.04%) | 3271 (10.09%) |
| Black | 125 (6.58%) | 717 (8.85%) | 842 (8.42%) | 307 (6.27%) | 1615 (8.30%) | 1922 (7.90%) | 535 (7.89%) | 2311 (9.01%) | 2846 (8.78%) |
| Hispanic | 670 (35.26%) | 2917 (36%) | 3587 (35.86%) | 2021 (41.30%) | 8154 (41.92%) | 10175 (41.8%) | 2698 (39.8%) | 10074 (39.29%) | 12772 (39.40%) |
| Other/Unknown | −8 (0.26%) | 940 (11.6%) | 945 (9.45%) | −8 (0.37%) | 1646 (8.46%) | 1664 (6.84%) | 31 (0.46%) | 3117 (12.16%) | 3148 (9.71%) |
| White | 922 (48.53%) | 2699 (33.31%) | 3621 (36.20%) | 2032 (41.52%) | 5910 (30.39%) | 7942 (32.62%) | 2819 (41.58%) | 7563 (29.5%) | 10382 (32.02%) |
| Cancer type group | |||||||||
| Acute lymphocytic leukemia | 15 (0.79%) | 49 (1.00%) | 77 (1.14%) | ||||||
| Acute myeloid leukemia | 34 (1.79%) | 94 (1.92%) | 126 (1.86%) | ||||||
| Bone | −8 (0.32%) | 45 (0.92%) | 69 (1.02%) | ||||||
| Brain | 59 (3.11%) | 190 (3.88%) | 268 (3.95%) | ||||||
| Breast | 259 (13.63%) | 766 (15.65%) | 1067 (15.74%) | ||||||
| Female genitourinary | 88 (4.63%) | 354 (7.23%) | 518 (7.64%) | ||||||
| Gastrointestinal | 156 (8.21%) | 255 (5.21%) | 373 (5.5%) | ||||||
| Hodgkin lymphoma | 76 (4.00%) | 301 (6.15%) | 394 (5.81%) | ||||||
| Lung | −8 (0.58%) | 51 (1.04%) | 69 (1.02%) | ||||||
| Multiple myeloma | −8 (0.74%) | −8 (0.29%) | 25 (0.37%) | ||||||
| Male genitourinary | 287 (15.11%) | 456 (9.32%) | 601 (8.87%) | ||||||
| Melanoma | 248 (13.05%) | 487 (9.95%) | 663 (9.78%) | ||||||
| Non-Hodgkin lymphoma | 101 (5.32%) | 245 (5.01%) | 341 (5.03%) | ||||||
| Oropharynx | 62 (3.26%) | 114 (2.33%) | 158 (2.33%) | ||||||
| Other | 105 (5.53%) | 225 (4.6%) | 330 (4.87%) | ||||||
| Ovary | 28 (1.47%) | 193 (3.94%) | 278 (4.10%) | ||||||
| Renal | 82 (4.32%) | 133 (2.72%) | 197 (2.91%) | ||||||
| Sarcoma | 35 (1.84%) | 98 (2.00%) | 143 (2.11%) | ||||||
| Thyroid | 234 (12.32%) | 824 (16.84%) | 1082 (15.96%) | ||||||
| TNM Stage | |||||||||
| Not Applicable | 245 (12.89%) | 646 (13.2%) | 925 (13.65%) | ||||||
| Stage I | 986 (51.89%) | 2478 (50.63%) | 3319 (48.96%) | ||||||
| Stage II | 342 (18%) | 916 (18.72%) | 1315 (19.4%) | ||||||
| Stage III | 179 (9.42%) | 448 (9.15%) | 644 (9.5%) | ||||||
| Stage IV | 85 (4.47%) | 204 (4.17%) | 296 (4.37%) | ||||||
| Unknown | 63 (3.32%) | 202 (4.13%) | 280 (4.13%) | ||||||
| Breast cancer screening4 |
Cervical cancer screening5 |
Colorectal cancer screening6 |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer survivors | Non-cancer group | Total | Cancer survivors | Non-cancer group | Total | Cancer survivors | Non-cancer group | Total | |
| (n = 191) | (n = 1308) | (n = 1499) | (n = 3697) | (n = 16313) | (n = 20010) | (n = 411) | (n = 1791) | (n = 2202) | |
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | |
| Follow-up period (years) | 2.4 (1.63) | 2.5 (1.63) | 2.5 (1.63) | 4.9 (3.74) | 5.1 (3.84) | 5.1 (3.82) | 2.3 (1.62) | 2.4 (1.63) | 2.4 (1.62) |
| Age7 | 37.5 (1.48) | 37.6 (1.45) | 37.6 (1.46) | 31.7 (6.23) | 32.1 (5.98) | 32.0 (6.03) | 37.5 (1.51) | 37.5 (1.48) | 37.5 (1.48) |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Age group7 | |||||||||
| 15–19 years | 219 (5.92%) | 795 (4.87%) | 1014 (5.07%) | ||||||
| 20–29 years | 924 (24.99%) | 3829 (23.47%) | 4753 (23.75%) | ||||||
| 30–39 years | 191 (100%) | 1308 (100%) | 1499 (100%) | 2554 (69.08%) | 11689 (71.65%) | 14243 (71.18%) | 411 (100%) | 1791 (100%) | 2202 (100%) |
| Sex | |||||||||
| Female | 191 (100%) | 1308 (100%) | 1499 (100%) | 3697 (100%) | 16313 (100%) | 20010 (100%) | 296 (72.02%) | 1309 (73.09%) | 1605 (72.89%) |
| Male | 115 (27.98%) | 482 (26.91%) | 597 (27.11%) | ||||||
| Race/ethnicity | |||||||||
| Asian/Pacific Islander | 32 (16.75%) | 145 (11.09%) | 177 (11.81%) | 446 (12.06%) | 1816 (11.13%) | 2262 (11.3%) | 46 (11.19%) | 190 (10.61%) | 236 (10.72%) |
| Black | -8 (7.85%) | 152 (11.62%) | 167 (11.14%) | 360 (9.74%) | 1670 (10.24%) | 2030 (10.14%) | 39 (9.49%) | 197 (11%) | 236 (10.72%) |
| Hispanic | 66 (34.55%) | 492 (37.61%) | 558 (37.22%) | 1420 (38.41%) | 6670 (40.89%) | 8090 (40.43%) | 144 (35.04%) | 638 (35.62%) | 782 (35.51%) |
| Other/Unknown | -8 (0%) | 33 (2.52%) | 33 (2.2%) | -8 (0.38%) | 1460 (8.95%) | 1474 (7.37%) | -8 (0%) | 77 (4.3%) | 77 (3.5%) |
| White | 78 (40.84%) | 486 (37.16%) | 564 (37.63%) | 1457 (39.41%) | 4697 (28.79%) | 6154 (30.75%) | 182 (44.28%) | 689 (38.47%) | 871 (39.55%) |
| Cancer type group | |||||||||
| Acute lymphocytic leukemia | –8 (1.05%) | –8 (0.54%) | –8 (0.97%) | ||||||
| Acute myeloid leukemia | –8 (0.52%) | 55 (1.49%) | –8 (0.73%) | ||||||
| Bone | –8 (0.73%) | –8 (0.24%) | |||||||
| Brain | –8 (4.19%) | 130 (3.52%) | –8 (2.92%) | ||||||
| Breast | 999 (27.02%) | 116 (28.22%) | |||||||
| Female genitourinary | 40 (20.94%) | 44 (1.19%) | 39 (9.49%) | ||||||
| Gastrointestinal | –8 (6.28%) | 158 (4.27%) | –8 (1.46%) | ||||||
| Hodgkin lymphoma | –8 (2.62%) | 194 (5.25%) | –8 (2.43%) | ||||||
| Lung | 41 (1.11%) | ||||||||
| Multiple myeloma | –8 (0.32%) | ||||||||
| Male genitourinary | –8 (6.57%) | ||||||||
| Melanoma | 34 (17.8%) | 412 (11.14%) | 57 (13.87%) | ||||||
| Non–Hodgkin lymphoma | –8 (3.66%) | 156 (4.22%) | –8 (5.6%) | ||||||
| Oropharynx | –8 (2.62%) | 67 (1.81%) | –8 (2.19%) | ||||||
| Other | –8 (3.66%) | 150 (4.06%) | –8 (3.65%) | ||||||
| Ovary | –8 (4.71%) | 185 (5%) | –8 (2.19%) | ||||||
| Renal | –8 (3.66%) | 78 (2.11%) | –8 (2.92%) | ||||||
| Sarcoma | –8 (1.05%) | 78 (2.11%) | –8 (1.22%) | ||||||
| Thyroid | 47 (24.61%) | 891 (24.1%) | 63 (15.33%) | ||||||
| TNM Stage | |||||||||
| Not Applicable | –8 (9.42%) | 400 (10.82%) | 33 (8.03%) | ||||||
| Stage I | 118 (61.78%) | 1803 (48.77%) | 208 (50.61%) | ||||||
| Stage II | –8 (13.09%) | 877 (23.72%) | 104 (25.3%) | ||||||
| Stage III | –8 (6.81%) | 319 (8.63%) | 37 (9%) | ||||||
| Stage IV | –8 (3.14%) | 137 (3.71%) | –8 (2.92%) | ||||||
| Unknown | –8 (5.76%) | 161 (4.35%) | –8 (4.14%) | ||||||
SD: standard deviation.
4 Recommended for females age 50–69 years.
5 Recommended for females age 21–65 years.
6 Recommended for individuals age 50–80 years.
1
Recommended for males age 35–65 years, females age 45–65 years.
2
Recommended for age ≥ 18 years; individuals who ended study prior to 2009 excluded.
3
Recommended for all ages.
7
For cancer survivors, age and age group indicate age at time of cancer diagnosis.
8
For N < 30, cell size is masked for protecting patient confidentiality; only the percentage is shown.